BioXcel Therapeutics, Inc. (BTAI) stock forecast & analysis
0.0739
NasdaqCM · USD
Down: -0.0436, -37.1%
0.0421Down: -0.0318, -43.0%
1 analysis
- Open
- 0.0910
- Previous close
- 0.1175
- Day range
- 0.0690 – 0.0935
- 52-week range
- 0.0690 – 4.29
- Volume (shares)
- 39.71M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 31.31M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.19
- Market cap
- 2.31M
Market Scanner’s AI analysis of BioXcel Therapeutics, Inc. (BTAI), updated September 2026: Teva Pharmaceuticals' asset acquisition agreement and BTAI's oversold technical indicators dominated recent analyses.
Summary
Teva Pharmaceuticals' asset acquisition agreement and BTAI's oversold technical indicators dominated recent analyses.
Recent analyses covered Teva Pharmaceuticals' agreement to acquire certain assets from BioXcel Therapeutics (BTAI) as part of Teva's growth strategy. The market analysis highlighted BTAI's significantly depressed stock price, trading well below its moving averages and near its 52-week low, with multiple technical indicators pointing to oversold conditions. The fundamentals analysis noted BTAI's positive quarterly revenue growth but also its persistent negative operating margins.
BTAI news & sentiment
News coverage focused on the acquisition agreement between Teva Pharmaceuticals and BioXcel Therapeutics, highlighting Teva's strategic growth initiative. Social media discussions were not covered in the provided notes.
BTAI technical picture
The stock price has experienced a steep and rapid decline, trading significantly below its 50-day and 200-day moving averages. Technical indicators suggest oversold conditions, though momentum readings remain negative.
Fundamentals
The company reported year-over-year quarterly revenue growth, but has consistently shown negative operating margins. The trailing twelve months revenue and gross profit were positive, though the EPS for the same period was negative.
Factors discussed — upside
- Quarterly revenue growth year-over-year of 51.7%
- Relative Strength Index (RSI) in oversold territory (21.13)
- Money Flow Index (MFI) low at 18.04
- Stock price near lower Bollinger Band
Factors discussed — risks
- Stock price significantly below 50-day and 200-day SMAs
- Steep and rapid price decline (7-day change at -83.6%)
- Negative MACD momentum
- Consistently negative operating margins (TTM -5600.5%)
- Stock price near 52-week low
- Asset acquisition
- Technical indicators
- Financial performance
- Oversold conditions
Summary updated .
BTAI technical indicators
Common technical indicators for BTAI, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.84 | Price below |
| 10-day exponential moving average | 0.33 | Price below |
| Relative strength index (14-day) | 20.17 | Oversold |
| MACD line (12/26/9) | -0.2196 | Below its signal line |
| Bollinger bands (20-day, 2σ) | -0.07 – 1.39 | Price inside the bands |
Analyses
Recent BTAI.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for BioXcel Therapeutics, Inc.?
- The bull case centers on BioXcel Therapeutics' recent quarterly revenue growth of over 51%, coupled with technical indicators suggesting oversold conditions. The stock price is currently near the lower Bollinger Band, and both the RSI and MFI are in oversold territory, hinting at potential for a rebound.
- What are the risks for BioXcel Therapeutics, Inc.?
- Risks for BioXcel Therapeutics include its stock trading significantly below key moving averages and near its 52-week low, accompanied by a steep recent price decline. Furthermore, the company has consistently reported negative operating margins, with a trailing twelve months figure of -5600.5%, and exhibits bearish momentum according to the MACD.
- Is BioXcel Therapeutics, Inc. bullish or bearish?
- Recent AI analyses of BioXcel Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case centers on BioXcel Therapeutics' recent quarterly revenue growth of over 51%, coupled with technical indicators suggesting oversold conditions. The stock price is currently near the lower Bollinger Band, and both the RSI and MFI are in oversold territory, hinting at potential for a rebound. Discussed risks: Risks for BioXcel Therapeutics include its stock trading significantly below key moving averages and near its 52-week low, accompanied by a steep recent price decline. Furthermore, the company has consistently reported negative operating margins, with a trailing twelve months figure of -5600.5%, and exhibits bearish momentum according to the MACD. These are descriptive observations, not a recommendation.
- What is the latest sentiment on BioXcel Therapeutics, Inc.?
- News coverage focused on the acquisition agreement between Teva Pharmaceuticals and BioXcel Therapeutics, highlighting Teva's strategic growth initiative. Social media discussions were not covered in the provided notes.
- Bundles used
- gemini-low-v2
Run a fresh BTAI.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every BTAI.US report already in the library